Impact of emerging ACA on survival in chronic myeloid leukemia (CML)

Leukemia. 2022 Oct;36(10):2544-2547. doi: 10.1038/s41375-022-01681-3. Epub 2022 Aug 23.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Imatinib Mesylate / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Leukemia, Myeloid*

Substances

  • Imatinib Mesylate